u/padawer metabolic triad: Zepbound (tirzepatide) + MOTS-c + CoQ10 ubiquinol — 60s, 25 lbs lost
A Synergistic Triad for Metabolic Health — Tirzepatide + MOTS-c + CoQ10 ... soliciting impressions, thoughts, opinions I posted an earlier version elsewhere — the revised version of this chart is based upon feedback. I'm taking Zepbound (the actual, perhaps overpriced, non-generic from Lilly), plus MOTS-c (reconstituted lyophilized peptide), plus CoQ10 (oral supplement ubiquinol from Amazon), and I've been trying to visualize the interaction. The results have been great for me — I'm a guy in his 60s desiring better health who's dropped 25 pounds so far (of 45 I need to lose) and have experienced a surge of energy. With each addition, I've seen and felt palpable improved energy — first, with the Zep; then more with the MOTS-c addition; and finally even more with the CoQ10 added.
A genuinely well-built metabolic stack. Older man chose Zepbound over compounded tirzepatide and is honest about why ('perhaps overpriced'). 25 pounds lost is a realistic outcome at this point in treatment, and the MOTS-c + CoQ10 additions are mechanistically coherent. Both target mitochondrial function, both have legitimate human data, both are reasonable adjuncts to a GLP-1-class protocol. The bounded gap is resistance training: GLP-1-mediated weight loss without a lifting program tilts loss toward lean mass, which matters more in your 60s than at 30.
| Goal | Score | Grade | Weight | Why |
|---|---|---|---|---|
| Longevity | 80 | B- | 20% | MOTS-c + tirzepatide-mediated metabolic improvement + CoQ10 in an older adult are all longevity-relevant choices. Stack is implicitly aimed at healthspan, even if the headline outcome is weight. |
| Cognition | — | Not targeted | — | No ingredient with a primary cognitive mechanism. Author reports an energy surge, not cognitive change. |
| Sleep & recovery | — | Not targeted | — | No ingredient with a sleep-targeted mechanism. |
| Energy & metabolism | 88 | B+ | 45% | Tirzepatide is one of the most-effective metabolic drugs ever approved. CoQ10 has solid evidence in older adults and statin users. MOTS-c has real mitochondrial mechanism with limited but legitimate human data. The combination is mechanistically coherent. |
| Body recomposition | 84 | B | 35% | 25 pounds lost of 45-pound target is a realistic Zepbound outcome at typical mid-titration doses. Held off the higher B range by the absence of any resistance training, which is the standard gap in GLP-1-mediated weight loss. |
Ingredients (3)
Tirzepatide (Zepbound)
Tirzepatide (Zepbound) on peptidelist.org ↗
- Dose
- unspecified · weekly
- Mechanism
- Dual GLP-1 / GIP receptor agonist. Phase 3 SURMOUNT-1 trial showed ~22% bodyweight loss at 72 weeks at the 15mg dose. FDA-approved as Zepbound for chronic weight management and as Mounjaro for type 2 diabetes.
- Take
- Author specifies he's using Zepbound (the FDA-approved branded product from Eli Lilly), not compounded tirzepatide. That choice matters. Compounded tirzepatide carries the same 'is it real, is it pure, is it the right concentration' risks as any research-vendor peptide; the FDA-approved supply chain doesn't. Zepbound through Lilly's self-pay LillyDirect program runs $299/mo, much closer to compounded pricing than the retail sticker most discussions cite. Dose escalation is standardized (2.5/5/7.5/10/12.5/15mg weekly subQ titration). Author doesn't disclose his current dose, but 25 pounds lost is consistent with mid-range titration.
MOTS-c
- Dose
- unspecified
- Mechanism
- Mitochondrial-derived 16-amino-acid peptide encoded by mitochondrial DNA. AMPK activator with metabolic effects on insulin sensitivity, glucose homeostasis, and exercise capacity in animal and small human studies.
- Take
- Author reconstitutes lyophilized peptide (the standard research-vendor format), so dosing is in his control but the source is the usual research-peptide market. Typical protocols use 5-10mg/week subQ. As a metabolic adjunct to tirzepatide, the rationale is mechanistically sound. MOTS-c activates AMPK and modulates insulin sensitivity, complementing the GLP-1/GIP effects rather than duplicating them. Combinatorial human data is essentially zero, but the components don't conflict.
CoQ10 (Ubiquinol)
- Dose
- unspecified
- Mechanism
- Lipid-soluble cofactor essential for mitochondrial electron transport (Complex I-III), and a primary endogenous antioxidant. Ubiquinol is the reduced (active) form. Endogenous synthesis declines with age and is depleted by statins.
- Take
- Author specifies ubiquinol (the reduced, more bioavailable form), which is the right choice for older adults. Endogenous CoQ10 declines with age and conversion of ubiquinone to ubiquinol slows. Effective doses for mitochondrial support are 100-300mg/day. The Amazon sourcing has typical retail-supplement variability, but reputable brands (Doctor's Best, Jarrow, Qunol) are well-tested. As a CoQ10 source supporting tirzepatide-mediated metabolic shifts and complementing MOTS-c's mitochondrial mechanism, the inclusion makes sense.
Risks & interactions
- GLP-1-mediated weight loss without resistance trainingmedium
Tirzepatide-driven weight loss tilts toward lean mass without a lifting program. The disproportionate lean-mass loss is well-documented across GLP-1 trials and matters more in older adults, where sarcopenic decline is already underway and harder to reverse. Author doesn't mention any training; if he's only doing the GLP-1 + supplements, his 25 pounds lost likely includes meaningful muscle.
- Tirzepatide GI side effectsmedium
GLP-1-class drugs cause significant nausea, vomiting, constipation, and diarrhea in a substantial minority of users, especially during titration. Author reports tolerating well enough to add MOTS-c on top, suggesting he's past the worst of it, but this is the standard failure mode.
- Research-peptide MOTS-c sourcinglow
Standard concern across research-vendor peptides: purity, sterility, endotoxin, and labeling can be off. Less central here than in stacks that depend on the research peptide for the headline effect, since the tirzepatide is doing most of the work.
- Three-compound stack with sequential additionlow
Author added Zepbound, then MOTS-c, then CoQ10 in sequence and reports incremental energy at each step. This is better methodology than most n=1 work in this space, but 'I felt better with each addition' is subject to expectancy effects. The sequential structure is a credibility upgrade rather than a credibility problem.
GLP-1-mediated weight loss tilts disproportionately toward lean mass without resistance training, and that's a bigger problem for a man in his 60s than for someone at 30. Sarcopenic decline is already underway at this age, and lean mass lost during a deficit is much harder to reclaim than fat. Two to three sessions per week of full-body progressive-resistance work would protect the strength and bone density that the energy surge alone won't. The MOTS-c is mechanistically interesting; the lifting would actually move the dial.
Estimated cost
Zepbound at LillyDirect self-pay pricing is $299/mo, much closer to compounded tirzepatide than the $1000+ retail sticker. MOTS-c at typical research-vendor pricing $40-80/mo. Ubiquinol CoQ10 from reputable retail brands $20-40/mo for 100-300mg/day. LillyDirect is the realistic cash-pay reference for Zepbound.